Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Steps to Extend Latency in Preterm Prelabor Rupture of Membranes (STEP)

6 de noviembre de 2026 actualizado por: Gabriela Dellapiana, Cedars-Sinai Medical Center

The goal of this quasi-experimental study is to determine if there are improved outcomes for patients with preterm prelabor rupture of membranes (PPROM) who walk daily. The main question it aims to answer is:

- Are patients with PPROM who walk at least 3500 steps per day more likely to stay pregnant longer than those who walk less?

Participants will be encouraged to walk ≥3500 steps per day from the time of diagnosis until delivery and their daily step counts will be recorded. Researchers will compare those who actually walk ≥3500 steps per day to those who walk less.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

The primary objective of this study is to determine if there is increased latency to delivery for patients with PPROM who ambulate ≥3500 steps per day compared to those who ambulate less. The investigators have chosen a goal of 3500 steps as this equates to approximately 30 minutes of moderate-intensity walking, and ACOG endorses the US Department of Health and Human Services Physical Activity Guidelines which recommend at least 150 minutes of moderate intensity aerobic activity per week during pregnancy.

The secondary objective of this study is to determine whether there is a lower risk of adverse maternal and neonatal outcomes for patients with PPROM who ambulate ≥3500 steps per day compared to those who ambulate less. Maternal adverse outcomes that will be assessed include rate of intra-amniotic infection, placental abruption, umbilical cord prolapse, cesarean delivery for non-reassuring fetal heart tracing, and thromboembolic events. Neonatal adverse outcomes that will be assessed include gestational age at delivery, birth weight, APGAR score at 5 minutes, requirement for NICU admission, length of stay, and neonatal death. The investigators will also assess the average steps per day for each participant and type of smartphone (i.e. Android vs iPhone).

Inclusion criteria include patients admitted to Cedars-Sinai with PPROM between the gestational ages of 24w0d and 33w6d who have planned inpatient management of at least 7 days, a phone capable of monitoring and sharing step count, and a singleton or dichorionic twin gestation. Exclusion criteria include patients with malpresentation (specifically, transverse, footling breech, or funic presentation), active preterm labor, or active vaginal bleeding.

This is a quasi-experimental study. All patients will be encouraged to ambulate ≥3500 steps per day. Patients will then be categorized into two cohorts: those who ambulated ≥3500 steps per day and those who ambulated <3500 steps per day. Outcomes will be compared between the two cohorts.

The duration of the study for each patient is the length of time from admission to delivery.

The study will be conducted at one site only, Cedars-Sinai.

At the time of study recruitment, patients will be given information about exercise in pregnancy and encouraged to ambulate at least 3500 steps per day. They will also be asked to share their daily step count via their smartphone health app with a member of the research team. All other antepartum, intrapartum, and postpartum care will be standard and/or per the primary obstetrician's discretion. After hospital discharge, a member of the research team will record the patient's daily step count and extract demographic information as well as obstetric and neonatal outcomes from the EMR.

Our primary outcome is the mean number of days of latency to delivery, and the investigators will use a Welch's t-test to assess the difference between our two study groups. The investigators will then use a multivariable linear regression analysis to account for potentially confounding variables.

For our secondary outcomes, the investigators will assess time from diagnosis to delivery using a log-rank test followed by a cox regression analysis. Additionally, maternal demographic and obstetric outcomes as well as neonatal outcomes will be compared using chi square and t-test for categorical and continuous variables, respectively.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

60

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Gabriela Dellapiana, MD
  • Número de teléfono: 3104237417

Ubicaciones de estudio

    • California
      • Los Angeles, California, Estados Unidos, 90048
        • Cedars-Sinai Medical Center
        • Contacto:
        • Contacto:
          • Gabriela Dellapiana, MD
          • Número de teléfono: 3104237417

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Planned inpatient expectant management of ≥7 days
  • Phone capable of monitoring and sharing step count
  • Singleton or dichorionic twin gestation

Exclusion Criteria:

  • Any records flagged "break the glass" or "research opt out"
  • Transverse, footling breech, or funic presentations
  • Active preterm labor
  • Active vaginal bleeding

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Encouraged to Ambulate

All patients will be encouraged to ambulate ≥3500 steps per day

Ambulate ≥3500 steps per day

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Days of latency until delivery
Periodo de tiempo: From hospital admission to delivery
From hospital admission to delivery

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of participants who experience a thromboembolic event
Periodo de tiempo: From admission until maternal hospital discharge, an average of 1-4 days after delivery
From admission until maternal hospital discharge, an average of 1-4 days after delivery
Number of participants who experience a postpartum hemorrhage
Periodo de tiempo: From admission until maternal hospital discharge, an average of 1-4 days after delivery

Postpartum hemorrhage is defined as EBL/QBL >= 1000mL

From admission until maternal hospital discharge, an average of 1-4 days after delivery
Number of participants who experience maternal sepsis
Periodo de tiempo: From admission until maternal hospital discharge, an average of 1-4 days after delivery
From admission until maternal hospital discharge, an average of 1-4 days after delivery
Number of participants who are admitted to the Intensive Care Unit (ICU)
Periodo de tiempo: From admission until maternal hospital discharge, an average of 1-4 days after delivery
From admission until maternal hospital discharge, an average of 1-4 days after delivery
Days of postpartum length of stay
Periodo de tiempo: From admission until maternal hospital discharge, an average of 1-4 days after delivery
From admission until maternal hospital discharge, an average of 1-4 days after delivery
Mode of delivery
Periodo de tiempo: Day of delivery

Vaginal delivery versus cesarean section

Day of delivery
Estimated or quantitative delivery blood loss
Periodo de tiempo: From admission until maternal hospital discharge, an average of 1-4 days after delivery
From admission until maternal hospital discharge, an average of 1-4 days after delivery
Number of participants who experience an intraamniotic infection
Periodo de tiempo: From admission until maternal hospital discharge, an average of 1-4 days after delivery
From admission until maternal hospital discharge, an average of 1-4 days after delivery
Number of patients who experience a placental abruption
Periodo de tiempo: From admission until delivery
From admission until delivery
Number of patients who experience an umbilical cord prolapse
Periodo de tiempo: From admission until delivery
From admission until delivery
Spontaneous versus induced labor
Periodo de tiempo: From admission until delivery
From admission until delivery
Indication for cesarean delivery
Periodo de tiempo: Day of delivery

Only for patients who deliver via cesarean delivery

Day of delivery
Gestational age at delivery
Periodo de tiempo: Day of delivery
Day of delivery
Neonatal birth weight
Periodo de tiempo: Day of delivery
Day of delivery
APGAR score at 5 minutes of life
Periodo de tiempo: 5 minutes of life on day of delivery

APGAR score (Appearance, Pulse, Grimace, Activity, and Respiration) is on a scale from 0-10. Lower scores indicate that infants are more likely to require resuscitation.

5 minutes of life on day of delivery
Umbilical cord blood gas values
Periodo de tiempo: Day of delivery

Arterial pH, CO2, and base excess

Day of delivery
Number of neonates who require Neonatal Intensive Care Unit (NICU) admission
Periodo de tiempo: From delivery until day of neonatal hospital discharge, varies based on gestational age at delivery
From delivery until day of neonatal hospital discharge, varies based on gestational age at delivery
Neonatal length of hospital stay
Periodo de tiempo: From delivery until day of neonatal hospital discharge, varies based on gestational age at delivery
From delivery until day of neonatal hospital discharge, varies based on gestational age at delivery
Number of participants who receive at least one course of antenatal corticosteroids
Periodo de tiempo: From admission until delivery
From admission until delivery
Number of participants who receive antenatal magnesium sulfate
Periodo de tiempo: From admission until delivery
From admission until delivery
Number of neonatal deaths
Periodo de tiempo: From admission until day of neonatal hospital discharge (or death when applicable), varies based on gestational age at delivery
From admission until day of neonatal hospital discharge (or death when applicable), varies based on gestational age at delivery

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Gabriela Dellapiana, MD, Cedars-Sinai Medical Center

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de noviembre de 2026

Finalización primaria (Estimado)

1 de diciembre de 2027

Finalización del estudio (Estimado)

1 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

19 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Publicado por primera vez (Actual)

13 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

13 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • STUDY00004892

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

To protect patient confidentiality

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .